Optinose Announces Departure of Chief Financial Officer

Rhea-AI Summary

Optinose (NASDAQ:OPTN) announced key leadership changes as Keith A. Goldan, CFO, departs for another opportunity, effective June 10, 2022. Michele Janis, VP of Finance, is appointed Acting CFO, while Anthony Krick becomes Vice President and Chief Accounting Officer. CEO Peter Miller praised Goldan’s contributions during the company's transition to a public entity. Janis and Krick are expected to maintain strong financial oversight and investor communication.

Positive

• Michele Janis has been part of Optinose since 2011, suggesting continuity in leadership.
• The leadership change aims to ensure stability in financial management and investor relations.

Negative

• The departure of an established CFO could lead to uncertainty during the transition.

Michele Janis Appointed Acting Chief Financial Officer

Anthony Krick Appointed Vice President & Chief Accounting Officer

YARDLEY, Pa., June 03, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Keith A. Goldan, Chief Financial Officer, will leave Optinose to accept a CFO opportunity at another public company. Mr. Goldan will continue to serve as Chief Financial Officer until his departure on June 10, 2022.

Chief Executive Officer Peter Miller stated, “On behalf of our entire team, I would like to thank Keith for his commitment and contributions to Optinose. His leadership made valuable contributions to Optinose as we successfully transitioned from being a private, development stage company to being a public, commercial stage company. And notably, he leaves us with the strong team of talented and capable finance and accounting professionals that he built.”

Michele Janis, Vice President of Finance, who joined Optinose in 2011, has served as a member of the Company’s leadership team since joining Optinose and will now serve as the Company’s Acting Chief Financial Officer. Anthony Krick, Vice President, Controller, will assume the newly created role of Vice President and Chief Accounting Officer and be responsible for financial reporting and managing the day to-day activities of the finance & accounting team. Jonathan Neely, Vice President, Investor Relations & Business Development will lead investor communications. He and Mr. Krick will also join the Company’s leadership team.

“It’s been a privilege to serve as the Optinose CFO and to have worked with such an exceptionally talented team,” said Keith Goldan, departing Chief Financial Officer.

About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S. and Norway. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531

FAQ

Who has been appointed as Optinose's Acting CFO?

Michele Janis is appointed as the Acting Chief Financial Officer.

When is Keith Goldan leaving Optinose?

Keith Goldan will leave Optinose on June 10, 2022.

What position will Anthony Krick hold at Optinose?

Anthony Krick has been appointed Vice President and Chief Accounting Officer.

What did CEO Peter Miller say about Keith Goldan's departure?

CEO Peter Miller thanked Goldan for his commitment and contributions during the transition to a public company.

What is the focus of Optinose as a pharmaceutical company?

Optinose focuses on patients treated by ear, nose, and throat (ENT) and allergy specialists.